NasdaqGS:TWSTBiotechs
How Upgraded Guidance And Breakeven Path At Twist Bioscience (TWST) Has Changed Its Investment Story
In early April 2026, Twist Bioscience reported strong fiscal first‑quarter results and raised its full‑year 2026 revenue guidance, while also outlining a path toward adjusted EBITDA breakeven by year‑end.
Despite this operational progress and continued institutional interest, some investors appear to be reassessing how much of the improved outlook is already embedded in expectations, leading to short‑term volatility.
We’ll now examine how Twist Bioscience’s upgraded full‑year revenue...